GlassScriptPhysician profile
Andrew Ondracek
NPI 1689251258
$3,922.93
in general payments reported to CMS, 2019-2025
16 companies · $1,572 in 2025
The $1,572 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $594 · 2023: $783 · 2024: $975 · 2025: $1,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,329.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $947.15 | 2022-2025 | |
| Madrigal Pharmaceuticals | $666.20 | 2024-2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $433.61 | 2022-2025 | Entyvio |
| Ardelyx, INC. | $340.00 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $261.73 | 2023-2025 | Livdelzi, Epclusa |
| Janssen Biotech, INC. | $244.75 | 2024-2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $211.58 | 2022-2024 | |
| Lilly USA, LLC | $177.03 | 2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $146.63 | 2023 | Zeposia |
| Boston Scientific Corporation | $138.29 | 2025 | Axonics |
| Novo Nordisk INC | $124.99 | 2022 | |
| Ferring Pharmaceuticals INC. | $122.12 | 2024 | Rebyota |
| Vivus LLC | $53.50 | 2024-2025 | Pancreaze |
| Pfizer INC. | $19.85 | 2024 | |
| Ironwood Pharmaceuticals, INC | $18.39 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $17.11 | 2024 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ondracek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.